Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTELLAR XR vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
FDA-approved as monotherapy or adjunctive therapy for partial-onset seizures in adults and children aged 4 years and older,Off-label: bipolar disorder, trigeminal neuralgia, diabetic neuropathy
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal half-life approximately 20-30 hours in adults; after multiple doses, effective half-life is about 24 hours, allowing once-daily dosing. Steady state reached in 4-5 days.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Oxcarbazepine is extensively metabolized by cytosolic enzymes to the active metabolite MHD (10,11-dihydro-10-hydroxy-carbazepine). MHD undergoes further glucuronidation and is excreted renally. Minor metabolism via CYP450 enzymes (CYP3A4/5) accounts for a small fraction.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily renal (70-80% as unchanged drug and metabolites) and fecal (20-30% via biliary excretion).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 40% bound to serum proteins, mainly albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.7-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Extended-release: 80-90% relative to immediate-release. No significant food effect.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
For creatinine clearance <30 m L/min: start at 150 mg twice daily (300 mg/day) and titrate slowly; patients with ESRD on dialysis: not recommended due to lack of data.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required. Severe hepatic impairment (Child-Pugh C): not studied; use with caution.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
For patients 6 years and older: oxcarbazepine XR (OXTELLAR XR) is not approved; use immediate-release oxcarbazepine based on weight: 8-10 mg/kg/day initially, titrated over 2 weeks to target 300-600 mg/day for 20-29 kg, 600-900 mg/day for 29.1-39 kg, 900-1200 mg/day for >39 kg. Not recommended under 6 years.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Elderly patients may have reduced clearance; start at 150 mg twice daily (300 mg/day) and titrate slowly. Monitor for hyponatremia, especially in those on diuretics or with low baseline sodium.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Hyponatremia (sodium <125 mmol/L) can occur, especially in elderly or patients on other hyponatremic drugs; monitor sodium levels,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue if rash develops,Suicidal behavior and ideation: monitor for worsening depression or suicidal thoughts,Dizziness, somnolence, ataxia: caution with activities requiring alertness,Multi-organ hypersensitivity reactions: discontinue if suspected,Withdrawal seizures: do not discontinue abruptly,Hematologic effects: rare agranulocytosis, aplastic anemia; monitor CBC if symptoms occur
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to oxcarbazepine or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Take with or without food consistently. Avoid grapefruit juice (may affect drug metabolism). No specific food restrictions but maintain consistent dietary habits to avoid fluctuations in absorption.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and cardiovascular anomalies, when used during the first trimester. In the second and third trimesters, use may be associated with adverse neurodevelopmental outcomes. The risk is dose-dependent and may be potentiated by concomitant antiepileptic drugs.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Oxcarbazepine and its active metabolite (MHD) are excreted into breast milk. The infant's plasma MHD concentration is approximately 10-30% of the maternal level, with M/P ratio for MHD estimated at 0.5-1.0. While generally considered compatible with breastfeeding, monitor the infant for drowsiness, poor feeding, and rash.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Due to increased clearance and volume of distribution during pregnancy, especially in the third trimester, dosage increments may be necessary to maintain therapeutic levels. Monitoring MHD trough concentrations and adjusting dose to achieve target levels is recommended. Postpartum, dose reduction may be required.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Oxtellar XR (oxcarbazepine extended-release) is a voltage-gated sodium channel blocker used as adjunctive therapy for partial-onset seizures. Titrate slowly to minimize CNS side effects; start at 600 mg/day and increase weekly by 300 mg/day to target 1200-2400 mg/day. Monitor serum sodium levels frequently, especially in elderly or patients on other hyponatremic drugs. Dose adjustments needed in renal impairment (Cr Cl <30 m L/min: start at 300 mg/day). A 20% increase in dose may be required when switching from immediate-release oxcarbazepine. CYP3A4/5 inducer; may reduce efficacy of hormonal contraceptives.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take once daily with or without food; swallow tablet whole, do not crush or chew.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy, weakness.,May cause dizziness, somnolence, or ataxia; avoid driving until effects known.,Serious skin reactions (SJS/TEN) possible; seek immediate care for rash or blisters.,Hormonal contraceptives may be less effective; use additional non-hormonal method.,Do not stop abruptly; taper to avoid withdrawal seizures.,Avoid alcohol; may worsen CNS depression.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTELLAR XR vs ACTIQ, answered by our medical review team.
OXTELLAR XR is a Opioid Analgesic that works by Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTELLAR XR and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTELLAR XR is: Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTELLAR XR and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTELLAR XR is classified as Category C. Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.